We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Key developments in "reverse payment" dispute: the Supreme Court agrees to weigh in, and a NJ court refuses to condemn exclusive authorized generics

17 December 2012

Antitrust, Competition and Economic Regulation Alert

This past week saw two key developments in the legal dispute over patent settlements including so-called “reverse payments.” First, the Supreme Court agreed to review an Eleventh Circuit decision dismissing a case brought by the Federal Trade Commission (FTC) challenging a patent settlement. Second, a district court in New Jersey issued the first decision to consider the legal treatment of a commitment by a brand name manufacturer to a generic company not to license any other generic companies the right to sell an authorized generic.

Read: "Key developments in "reverse payment" dispute: the Supreme Court agrees to weigh in, and a NJ court refuses to condemn exclusive authorized generics"

The team

Loading data